Researchers have developed an algorithm to accurately predict which patients diagnosed with acute myelogenous leukemia (AML), a cancer of the blood and bone marrow, will go into remission following treatment and which ones will relapse.

Using bone marrow data and medical histories of AML patients, as well as blood data from healthy individuals, researchers were able to teach a standard 64-bit computer workstation running Windows to predict remission with 100 percent accuracy, while relapse was correctly predicted in 90 percent of relevant cases.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access